U.S. Markets open in 6 hrs 33 mins

CytRx issued European patent covering INNO-206 linker technology

CytRx Corporation announced that the European Patent Office has issued a patent covering the Company’s tumor-targeting linker platform technology and pharmaceutical compositions. CytRx also unveiled aldoxorubucin as the new generic name for INNO-206, the conjugate comprised of the protein-binding linker technology and the commonly prescribed chemotherapeutic drug doxorubicin.